about us

about us

Our history

2008
  • Shaperon is established
2016
  • Approved by KFDA for atopic dermatitis clinical phase I
2018
  • Started NuGel® Phase I trial for atopic dermatitis
2019
  • Started NuSepin® Phase I trial for sepsis
  • Alzheimer’s disease program selected as government-sponsored research project to develop breakthrough therapeutics
2020
  • Started NuGel® Phase II trial for atopic dermatitis
  • Completed NuSepin® Phase I trial for sepsis
  • Started NuSepin® Phase II trial for Covid 19
  • Nanobody production platform technology selected as government-sponsored research project
2021
  • MOU signed with Cellbion Co
  • Licensing out agreement with Kukjeon pharmaceutical company
  • Strategic collaboration agreement with Dong-A ST to co-develop multiple novel biologic therapies in cancer and inflammatory diseases
  • Nanobody co-development agreement with Korea Research Institute of Bioscience and Biotechnology